13 February 2017

Total Voting Rights & Block Listing Interim Review

RNS Number : 6715W
Verona Pharma PLC
13 February 2017

Verona Pharma plc
("Verona Pharma" or the "Company")

Total Voting Rights
Block Listing Interim Review

13 February 2017, London - Verona Pharma plc (AIM: VRP), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces an update to its total voting rights and a block listing interim review.

The Company confirms that, following the 50 for 1 share consolidation approved by shareholders on 8 February 2017, Verona Pharma now has 51,361,064 ordinary shares of £0.05 each ("Ordinary Shares") in issue, each carrying one voting right.  The Company has no shares in treasury. Accordingly the figure of 51,361,064 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

From 8:00 a.m. today, the Company's shares will trade under ISIN GB00BYW2KH80 and SEDOL number BYW2KH8.

Verona Pharma has a block listing issued in respect of Ordinary Shares which may arise pursuant to the exercise of warrants issued in connection with the placing completed in July 2016 ("Warrant Shares").  An interim update is included below for the purposes of AIM Rule 29, confirming that there are 10,262,879 of the newly consolidated Ordinary Shares which are currently block listed.

Name of applicant:

Verona Pharma plc

Name of scheme:

2016 Warrant Shares

Period of return:

From:

1 August 2016

To:

10 February 2017

Balance of unallotted securities under scheme(s) from previous return:

(1)  Pre consolidation:              513,143,965

(2)  Post consolidation:              10,262,879

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

(2)                        Nil

 

Less:  Number of securities issued/allotted under scheme(s) during period:

(2)                        Nil

Less: Number of options over securities which have now lapsed:

(2)                        Nil

 

Equals: Balance under schemes not yet issued/allotted at end of period:

(2)            10,262,879

 
         

Number and class of securities originally admitted:

(1)  Pre consolidation: 513,143,965

(2)  Post consolidation: 10,262,879

Dates of admission:

(1)  29 July 2016

(2)  13 February 2017

 

Name of contact:

Piers J Morgan

Telephone number of contact:

+44 (0)20 3283 4200

-Ends-

For further information please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer

Tel: +44 (0)20 3283 4200

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White

Tel: +44 (0)20 7496 3000

FTI Consulting
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins

Tel: +44 (0)20 3727 1000

Notes to Editors

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. 

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti‑inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

This information is provided by RNS
The company news service from the London Stock Exchange

END

TVRMMGMZZZDGNZZ


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us